Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.

Simona Di Giambenedetto, Enrica Tamburrini, Roberto Cauda, Manuela Colafigli, Laura Bracciale, Andrea De Luca, 33189, DI MEDICINA E CHIRURGIA "A.GEMELLI" FACOLTA', ROMA - Dipartimento di Sicurezza e Bioetica

Risultato della ricerca: Contributo in rivistaArticolo in rivista

26 Citazioni (Scopus)


BACKGROUND: We aimed to establish whether the limited impact of atazanavir on the plasma lipid profile could translate into a reduction in the predicted cardiovascular risk in antiretroviral (ARV)-experienced patients switching to an atazanavir-containing regimen. METHODS: HIV-1-infected treatment-experienced patients, switched to atazanavir for whatever reason and without prior major cardiovascular events, were selected and followed for at least 1 month. An individual cardiovascular risk score (10-year risk of major cardiovascular events) based on validated events and measurable risk factors in Italian cardiovascular cohorts was calculated using software available online. RESULTS: A total of 197 patients were selected for inclusion in the study. After switching to atazanavir, the mean changes from pre-switch to last available measurement were -6.5% (P<0.001) for total cholesterol, -1.7% (P=0.029) for high-density lipoprotein (HDL) cholesterol, -11.3% (P<0.001) for non-HDL cholesterol and -8.6% (P<0.001) for triglycerides. The crude cardiovascular risk score was reduced from 3.43 to 3.38% (P=0.51); the analysis normalized by age showed a reduction from 3.43 to 3.14% (P<0.001). Subsets of patients with high baseline total cholesterol or triglycerides showed more marked reductions. CONCLUSIONS: A treatment switch to atazanavir caused significant reductions in plasma lipids and a modest but significant reduction in the normalized-for-age cardiovascular risk score. Efforts should be made to concomitantly reduce the other preventable cardiovascular risk factors
Lingua originaleEnglish
pagine (da-a)172-179
Numero di pagine8
RivistaHIV Medicine
Stato di pubblicazionePubblicato - 2008


  • HIV
  • atazanavir
  • cardiovascular


Entra nei temi di ricerca di 'Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.'. Insieme formano una fingerprint unica.

Cita questo